🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06388174
Recruiting Observational

Idiopathic Generalized Epilepsy Syndromes

NCT06388174 · tracked via the Priya Life Science China tracker
Sponsor
Shen Chun-Hong
Phase
Observational
Started
2023-01-01
Last updated
2025-08-27

Condition(s) studied

EpilepsyEpilepsy, Idiopathic Generalized

Study summary

The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance.

According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

Eligibility

Sex
ALL
Min age
4 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy. * Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria. * Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed. * Sign the informed consent forms. Exclusion Criteria: * Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy. * Lost to follow-up

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China Hangzhou Zhejiang Recruiting

More Shen Chun-Hong trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06388174 on ClinicalTrials.gov ↗ ← All trials in China